Updates and prospect of neoadjuvant radiotherapy for early breast cancer
Wang Xueer1,2, Jiang Jie2,3, Huang Wei2, Li Baosheng2
1Shandong First Medical University, Ji'nan 250117, China; 2Department of Thoracic Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji'nan 250117, China; 3Weifang Medical University, Weifang 261053, China
Abstract：Adjuvant radiotherapy has become an important part of the standard treatment for breast cancer. Compared with the traditional postoperative radiotherapy, neoadjuvant radiotherapy has the theoretical advantages of more accurate target delineation, optimization of radiation strategy for breast reconstruction, increase of breast conservation surgery with tumor down‐staging and avoiding breast surgery by improving pathological complete response rate, which have been confirmed by recent clinical research. Prospective studies are still needed for the optimal target delineation, dose fractionation, radiation‐surgery interval, and combination with systemic therapies, aiming to provide the optimal treatment option for patients with early breast cancer.
Wang Xueer,Jiang Jie,Huang Wei et al. Updates and prospect of neoadjuvant radiotherapy for early breast cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(12): 1174-1178.
[1] Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials[J]. Lancet, 2011,378(9804):1707-1716. DOI: 10.1016/S0140-6736(11)61629-2. [2] Castaneda SA, Strasser J.Updates in the treatment of breast cancer with radiotherapy[J]. Surg Oncol Clin N Am, 2017,26(3):371-382. DOI: 10.1016/j.soc.2017.01.013. [3] Colleoni M, Nole F, Minchella I, et al.Pre-operative chemotherapy and radiotherapy in breast cancer[J]. Eur J Cancer, 1998,34(5):641-645. DOI: 10.1016/s0959-8049(97)10091-0. [4] Lerouge D, Touboul E, Lefranc JP, et al.Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients[J]. Int J Radiat Oncol Biol Phys, 2004,59(4):1062-1073. DOI: 10.1016/j.ijrobp.2003.12.034. [5] van der Leij F, Bosma SC, van de Vijver MJ, et al. First results of the preoperative accelerated partial breast irradiation (PAPBI) trial[J]. Radiother Oncol, 2015,114(3):322-327. DOI: 10.1016/j.radonc.2015.02.002. [6] Nichols E, Kesmodel SB, Bellavance E, et al.Preoperative accelerated partial breast irradiation for early-stage breast cancer: preliminary results of a prospective, phase 2 trial[J]. Int J Radiat Oncol Biol Phys, 2017,97(4):747-753. DOI: 10.1016/j.ijrobp.2016.11.030. [7] Lightowlers SV, Boersma LJ, Fourquet A, et al.Preoperative breast radiation therapy: indications and perspectives[J]. Eur J Cancer, 2017,82:184-192. DOI: 10.1016/j.ejca.2017.06.014. [8] Corradini S, Krug D, Meattini I, et al.Preoperative radiotherapy: a paradigm shift in the treatment of breast cancer? a review of literature[J]. Crit Rev Oncol Hematol, 2019,141:102-111. DOI: 10.1016/j.critrevonc.2019.06.003. [9] Hepel JT, Tokita M, MacAusland SG, et al. Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation[J]. Int J Radiat Oncol Biol Phys, 2009,75(5):1290-1296. DOI: 10.1016/j.ijrobp.2009.01.009. [10] Lightowlers SV, Boersma LJ, Fourquet A, et al.Preoperative breast radiation therapy: indications and perspectives[J]. Eur J Cancer, 2017,82:184-192. DOI: 10.1016/j.ejca.2017.06.014. [11] Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials[J]. Lancet Oncol, 2018,19(1):27-39. DOI: 10.1016/S1470-2045(17)30777-5. [12] Brandão M, Reyal F, Hamy AS, et al.Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation[J]. ESMO Open, 2019,4(3):e000515. DOI: 10.1136/esmoopen-2019-000515. [13] Li Y, Zhou Y, Mao F, et al.The diagnostic performance of minimally invasive biopsy in predicting breast pathological complete response after neoadjuvant systemic therapy in breast cancer: a meta-analysis[J]. Front Oncol, 2020,10:933. DOI: 10.3389/fonc.2020.00933. [14] Marous M, Bièche I, Paoletti X, et al.Designs of preoperative biomarkers trials in oncology: a systematic review of the literature[J]. Ann Oncol, 2015,26(12):2419-2428. DOI: 10.1093/annonc/mdv378. [15] Bosma S, Hoogstraat M, van der Leij F, et al. Response to preoperative radiation therapy in relation to gene expression patterns in breast cancer patients[J]. Int J Radiat Oncol Biol Phys, 2020,106(1):174-181. DOI: 10.1016/j.ijrobp.2019. 09.002. [16] Tanić M, Krivokuća A, Čavić M, et al.Molecular signature of response to preoperative radiotherapy in locally advanced breast cancer[J]. Radiat Oncol, 2018,13(1):193. DOI: 10.1186/s13014-018-1129-4. [17] Beal K, McCormick B. Consensus statement: APBI from ASTRO (Int J Radiat Oncol Biol Phys2009;74:987-1001)[J]. Int J Radiat Oncol Biol Phys, 2010,76(2):638; author reply 638-639. DOI: 10.1016/j.ijrobp.2009.09.014. [18] Kirby AM.Updated ASTRO guidelines on accelerated partial breast irradiation (APBI): to whom can we offer APBI outside a clinical trial?[J]. Br J Radiol, 2018,91(1085):20170565. DOI: 10.1259/bjr.20170565. [19] Polgár C, Van Limbergen E, Pötter R, et al.Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009)[J]. Radiother Oncol, 2010,94(3):264-273. DOI: 10.1016/j.radonc.2010. 01.014. [20] Bosma S, Leij F, Vreeswijk S, et al.Five-year results of the preoperative accelerated partial breast irradiation (PAPBI) trial[J]. Int J Radiat Oncol Biol Phys, 2020,106(5):958-967. DOI: 10.1016/j.ijrobp.2019.12.037. [21] The Netherlands Cancer Institute. Pre‐versus postoperative accelerated partial breast irradiation[EB/OL].(2016-09-26)[2021-06-04].https://clinicaltrials.gov/ct2/show/NCT02913729. [22] Vasmel JE, Charaghvandi RK, Houweling AC, et al.Tumor response after neoadjuvant magnetic resonance guided single ablative dose partial breast irradiation[J]. Int J Radiat Oncol Biol Phys, 2020,106(4):821-829. DOI: 10.1016/j.ijrobp.2019.11.406. [23] Guidolin K, Yaremko B, Lynn K, et al.Stereotactic image-guided neoadjuvant ablative single-dose radiation, then lumpectomy, for early breast cancer: the SIGNAL prospective single-arm trial of single-dose radiation therapy[J]. Curr Oncol, 2019,26(3):e334-e340. DOI: 10.3747/co.26.4479. [24] Horton JK, Blitzblau RC, Yoo S, et al.Preoperative single-fraction partial breast radiation therapy: a novel phase 1, dose-escalation protocol with radiation response biomarkers[J]. Int J Radiat Oncol Biol Phys, 2015,92(4):846-855. DOI: 10.1016/j.ijrobp.2015.03.007. [25] Tanić M, Krivokuća A, Čavić M, et al.Molecular signature of response to preoperative radiotherapy in locally advanced breast cancer[J]. Radiat Oncol, 2018,13(1):193. DOI: 10.1186/s13014-018-1129-4. [26] Schmitz AC, van den Bosch MA, Loo CE, et al. Precise correlation between MRI and histopathology - exploring treatment margins for MRI-guided localized breast cancer therapy[J]. Radiother Oncol, 2010,97(2):225-232. DOI: 10.1016/j.radonc.2010.07.025. [27] Pilones KA, Joseph A, Vatner R, et al.Radiation therapy sensitizes a poorly immunogenic breast cancer to PD-1 blockade[J]. Int J Radiat Oncol Biol Phys, 2014,90(1):S58.DOI:10.1016/j.ijrobp.2014.05.203. [28] Park SS, Dong H, Liu X, et al.PD-1 restrains radiotherapy- induced abscopal effect[J]. Cancer Immunol Res, 2015,3(6):610-619. DOI: 10.1158/2326-6066.CIR-14-0138. [29] Young KH, Baird JR, Savage T, et al.Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy[J]. PLoS One, 2016,11(6):e0157164. DOI: 10.1371/journal.pone.0157164. [30] Monrigal E, Dauplat J, Gimbergues P, et al.Mastectomy with immediate breast reconstruction after neoadjuvant chemotherapy and radiation therapy. A new option for patients with operable invasive breast cancer. Results of a 20 years single institution study[J]. Eur J Surg Oncol, 2011,37(10):864-870. DOI: 10.1016/j.ejso.2011.07.009. [31] Brackstone M, Baldassarre FG, Perera FE, et al.Management of the axilla in early-stage breast cancer: Ontario Health (Cancer Care Ontario) and ASCO guideline[J]. J Clin Oncol, 2021,39(27):3056-3082. DOI: 10.1200/JCO.21.00934.
2022, Vol. 31 
